‘Pincer attack’ on transcription factors offers new possibilities for future blood cancer therapies

The simultaneous inhibition of the transcription factors Myc and JunB could represent a pioneering therapeutic option for the treatment of multiple myeloma (MM), the second most common type of blood cancer.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup